PeptideScanner
U.S. label record↗Bone↗

Teriparatide↗

A parathyroid hormone analogue. This profile cites a U.S. label record.↗

Citation markers ↗ open the public records supporting the adjacent statements.

Profile update · July 27, 2026

We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change. 1

This version supersedes public version 1.

Start here

The evidence at a glance

What is its status in the cited records?

U.S. label record. The cited DailyMed label identifies Teriparatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗

Status sources checked through July 22, 2026. See status sources and coverage →

What do the reviewed human studies say?

Human evidence reviewed August 19, 2026 · Review version 1.

Review source snapshots checked August 19, 2026 · Integrity checked August 19, 2026.

A bounded review of two randomized fracture trials in postmenopausal women with osteoporosis, including one placebo comparison and one active comparison with risedronate.↗↗

What the reviewed sources report

Both reviewed trials reported fewer new vertebral fractures with teriparatide than with the comparator. The active-comparator trial did not find a statistically significant difference for its nonvertebral fragility-fracture endpoint.↗↗

What remains unresolved?

  • How do fracture outcomes, harms, and persistence compare across broader osteoporosis populations and after the reviewed treatment windows?↗↗

Read study designs, results, limitations, and sources →

What does the U.S. product label say?

Teriparatide injection · Read September 15, 2026 · Preserved label summary 1

Which population and use does the label cover?

The label covers specified high-fracture-risk osteoporosis settings in postmenopausal women, men with primary or hypogonadal osteoporosis, and men or women with glucocorticoid-associated osteoporosis. The male indication refers to increasing bone mass; the postmenopausal account includes fracture-risk reduction. Label: 1 ↗

Which safety limits matter?

The label contraindicates hypersensitivity and addresses osteosarcoma risk, hypercalcemia, cutaneous calcification including calciphylaxis, urinary stones and orthostatic hypotension. It distinguishes the rat osteosarcoma finding from observational human studies in which an increased risk was not observed. Label: 4, 5 ↗

Label edition and source pins

U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.

Teriparatide injection, solution · SPL version 9 · published 2026-06-30

Label ZIP SHA-256: 3d44d13e5c26a6d99016811b324c701e16b0d18d7390d19dd9e3ee5833bb6cb8. Extracted XML SHA-256: a86aaababbba9a8a6ddf6737fbd40d6ecf891c291bb211b5722997e127bf509b.

Open versioned label context data →

Reviews summarize selected studies; their scope and limitations are shown above.

European medicine records · 12 products or applications

EMA medicine metadata checked 2026-09-15. These are product-specific centralized records; national European authorizations and full product-information assessments require separate coverage.

Application withdrawal and refusal are distinct from marketing authorization. A withdrawal status alone does not establish why it occurred. These metadata entries do not substitute for indication, population or safety details in the relevant product information.

Open versioned records and source-feed pins →

Research coverage and study families

Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.

Open machine-readable coverage and record decisions →

PubMed search

Catalog-name and calibrated alias discovery for human evidence review. Complete query retrieval is separate from clinical eligibility, study-family linkage and appraisal.

5262 retrieved · 2 included · 0 excluded · 5260 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

"Teriparatide"[Title/Abstract] OR "parathyroid hormone (1-34)"[Title/Abstract] OR "PTH(1-34)"[Title/Abstract] OR "Teriparatide"[Substance Name]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:05:36.275357+00:00 · HTTP 200 · SHA-256 403f79d926885a3f4b6c784057d65021858330f52585dd90f4c2af330edafc12.

  • Retrieved IDs completely represent this query response, not all relevant literature. Additional aliases, references and non-PubMed sources require separate searches.
  • Unscreened records may include animal or cell experiments, reviews, secondary analyses, mixtures, protocols and unrelated name matches.
  • Study-family mappings use available declared registry IDs; unresolved mappings do not create independent trial counts. Full-text, corrections and registry comparison remain separate work.
  • Linked correction notices require comparison with the selected reports: PMID29198559 for PMID29129436, PMID30527615 for PMID29129436. Their presence does not establish what changed.
  • Older PTH(1-34) and substance-index searches recover older reports; endogenous physiology and other parathyroid preparations need separate screening.

Showing 25 of 5262 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. PubMed 29129436 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT01709110.
    Bibliographic record recheck · 2026-09-15

    The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗

    SHA-256 36f2e43b6083d116716442ec30a08f20413f3bbae83e308678d58c0ec185b2f1.

    • PubMed links an erratum: Department of Error. ↗. Impact on the selected study summary remains unresolved.

      Notice XML SHA-256 665a17b3bf95b6880447142e0ff4644a89dcbf3dd0d8b9de4a22c0d9a3f554e0.

    • PubMed links an erratum: Department of Error. ↗. Impact on the selected study summary remains unresolved.

      Notice XML SHA-256 ec5be10c5fc7192f7e1a4a3310a31413c4f12070b431d9ee36600a6a05d0dfa0.

  2. PubMed 11346808 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: teriparatide-PMID11346808-registry-linkage-unresolved.
    Bibliographic record recheck · 2026-09-15

    The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗

    SHA-256 6e178a71aed55efb345f0b59ad938e7c5c0db5692d911f30c23ae4d66e0627b2.

  3. PubMed 42734616 — not screened: Name-query match awaiting clinical eligibility screening.
  4. PubMed 42684545 — not screened: Name-query match awaiting clinical eligibility screening.
  5. PubMed 42671953 — not screened: Name-query match awaiting clinical eligibility screening.
  6. PubMed 42656047 — not screened: Name-query match awaiting clinical eligibility screening.
  7. PubMed 42652552 — not screened: Name-query match awaiting clinical eligibility screening.
  8. PubMed 42648994 — not screened: Name-query match awaiting clinical eligibility screening.
  9. PubMed 42635746 — not screened: Name-query match awaiting clinical eligibility screening.
  10. PubMed 42635731 — not screened: Name-query match awaiting clinical eligibility screening.
  11. PubMed 42616119 — not screened: Name-query match awaiting clinical eligibility screening.
  12. PubMed 42614145 — not screened: Name-query match awaiting clinical eligibility screening.
  13. PubMed 42611824 — not screened: Name-query match awaiting clinical eligibility screening.
  14. PubMed 42611745 — not screened: Name-query match awaiting clinical eligibility screening.
  15. PubMed 42605157 — not screened: Name-query match awaiting clinical eligibility screening.
  16. PubMed 42672530 — not screened: Name-query match awaiting clinical eligibility screening.
  17. PubMed 35442604 — not screened: Name-query match awaiting clinical eligibility screening.
  18. PubMed 42597939 — not screened: Name-query match awaiting clinical eligibility screening.
  19. PubMed 42597795 — not screened: Name-query match awaiting clinical eligibility screening.
  20. PubMed 42592840 — not screened: Name-query match awaiting clinical eligibility screening.
  21. PubMed 42590191 — not screened: Name-query match awaiting clinical eligibility screening.
  22. PubMed 42587612 — not screened: Name-query match awaiting clinical eligibility screening.
  23. PubMed 42584962 — not screened: Name-query match awaiting clinical eligibility screening.
  24. PubMed 42583280 — not screened: Name-query match awaiting clinical eligibility screening.
  25. PubMed 42579011 — not screened: Name-query match awaiting clinical eligibility screening.

FDA search

Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.

7 retrieved · 7 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

products.active_ingredients.name:"TERIPARATIDE"

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:10:29.773922+00:00 · HTTP 200 · SHA-256 3b5f560d25b6b0138de7f3cdf73d3eb38c6a923ef756b9d53a53bc7e647b7d83.

  • Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
  • This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.

Showing 7 of 7 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. FDA ANDA208569 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: TERIPARATIDE.
  2. FDA NDA019498 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: TERIPARATIDE ACETATE.
  3. FDA ANDA211097 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: TERIPARATIDE.
  4. FDA ANDA213641 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: TERIPARATIDE.
  5. FDA NDA218771 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: TERIPARATIDE.
  6. FDA NDA021318 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: TERIPARATIDE.
  7. FDA NDA211939 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: TERIPARATIDE.

EMA search

Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.

12 retrieved · 12 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

Case-insensitive word-boundary identity terms: ["Teriparatide"]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:34:22.905972+00:00 · HTTP 200 · SHA-256 a947c2b8a56ac2b92ec96156843f262f5e516f83b375d6791d67a8f6dc695729.

  • Document appraisal and national European sources remain open.
  • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

Showing 12 of 12 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. EMA EMEA/H/C/004932 — include: EMA feed product Kauliv; reported status: Authorised. Exact indication and decision documents remain unappraised.
  2. EMA EMEA/H/C/006688 — include: EMA feed product Zandoriah; reported status: Authorised. Exact indication and decision documents remain unappraised.
  3. EMA EMEA/H/C/003916 — include: EMA feed product Terrosa; reported status: Authorised. Exact indication and decision documents remain unappraised.
  4. EMA EMEA/H/C/004368 — include: EMA feed product Movymia; reported status: Authorised. Exact indication and decision documents remain unappraised.
  5. EMA EMEA/H/C/005827 — include: EMA feed product Sondelbay; reported status: Authorised. Exact indication and decision documents remain unappraised.
  6. EMA EMEA/H/C/000425 — include: EMA feed product Forsteo; reported status: Authorised. Exact indication and decision documents remain unappraised.
  7. EMA EMEA/H/C/005087 — include: EMA feed product Livogiva; reported status: Authorised. Exact indication and decision documents remain unappraised.
  8. EMA EMEA/H/C/005793 — include: EMA feed product Teriparatide Sun; reported status: Authorised. Exact indication and decision documents remain unappraised.
  9. EMA EMEA/H/C/005687 — include: EMA feed product Teriparatide Ascend; reported status: Application withdrawn. Exact indication and decision documents remain unappraised.
  10. EMA EMEA/H/C/005543 — include: EMA feed product Teriparatide Cinnagen; reported status: Application withdrawn. Exact indication and decision documents remain unappraised.
  11. EMA EMEA/H/C/005388 — include: EMA feed product Qutavina; reported status: Withdrawn. Exact indication and decision documents remain unappraised.
  12. EMA EMEA/H/C/005233 — include: EMA feed product Sondelbay; reported status: Application withdrawn. Exact indication and decision documents remain unappraised.

EMA search

Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.

75 retrieved · 67 included · 0 excluded · 8 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

Case-insensitive word-boundary identity terms: ["Teriparatide"]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:34:29.167460+00:00 · HTTP 200 · SHA-256 c0c68d7d77783e0355cbc75bdd04772e9acc163236fc68abcd794477c4c3d439.

  • Document appraisal and national European sources remain open.
  • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

Showing 25 of 75 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. EMA 13908 — include: Document linked by EMA product number; content unappraised. Forsteo : EPAR - All Authorised presentations
  2. EMA 15954 — include: Document linked by EMA product number; content unappraised. Terrosa : EPAR - Summary for the public
  3. EMA 20033 — include: Document linked by EMA product number; content unappraised. Terrosa : EPAR - All Authorised presentations
  4. EMA 27346 — include: Document linked by EMA product number; content unappraised. Movymia : EPAR - Summary for the public
  5. EMA 27569 — include: Document linked by EMA product number; content unappraised. Forsteo : EPAR - Scientific Discussion
  6. EMA 27862 — include: Document linked by EMA product number; content unappraised. Forsteo : EPAR - Summary for the public
  7. EMA 32446 — include: Document linked by EMA product number; content unappraised. Terrosa : EPAR - Public assessment report
  8. EMA 32824 — include: Document linked by EMA product number; content unappraised. Movymia : EPAR - All Authorised presentations
  9. EMA 33492 — include: Document linked by EMA product number; content unappraised. Forsteo-H-C-425-II-11 : EPAR - Scientific Discussion - Variation
  10. EMA 35838 — include: Document linked by EMA product number; content unappraised. Movymia : EPAR - Public assessment report
  11. EMA 37589 — include: Document linked by EMA product number; content unappraised. Forsteo : EPAR - Procedural steps taken before authorisation
  12. EMA 38968 — include: Document linked by EMA product number; content unappraised. Forsteo-H-C-425-II-13 : EPAR - Scientific Discussion - Variation
  13. EMA 49151 — include: Document linked by EMA product number; content unappraised. Terrosa : EPAR - Risk-management-plan summary
  14. EMA 49156 — include: Document linked by EMA product number; content unappraised. Movymia : EPAR - Risk-management-plan summary
  15. EMA 49730 — include: Document linked by EMA product number; content unappraised. Livogiva : EPAR - All authorised presentations
  16. EMA 49731 — include: Document linked by EMA product number; content unappraised. Livogiva : EPAR - Medicine overview
  17. EMA 49733 — include: Document linked by EMA product number; content unappraised. Livogiva : EPAR - Public assessment report
  18. EMA 49820 — include: Document linked by EMA product number; content unappraised. Qutavina : EPAR - Medicine overview
  19. EMA 49823 — include: Document linked by EMA product number; content unappraised. Qutavina : EPAR - All Authorised presentations
  20. EMA 49824 — include: Document linked by EMA product number; content unappraised. Qutavina : EPAR - Risk-management-plan summary
  21. EMA 49825 — include: Document linked by EMA product number; content unappraised. Qutavina : EPAR - Public assessment report
  22. EMA 50638 — include: Document linked by EMA product number; content unappraised. Forsteo : EPAR - Risk-management-plan summary
  23. EMA 55260 — include: Document linked by EMA product number; content unappraised. Sondelbay : EPAR - Medicine overview
  24. EMA 55263 — include: Document linked by EMA product number; content unappraised. Sondelbay : EPAR - Risk-management-plan summary
  25. EMA 55298 — include: Document linked by EMA product number; content unappraised. Sondelbay : EPAR - Public Assessment Report

EMA search

Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.

2 retrieved · 1 included · 1 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

Case-insensitive word-boundary identity terms: ["Teriparatide"]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:34:31.262344+00:00 · HTTP 200 · SHA-256 7448bf4e77e3345b3f3fbb7062c335d2302d8ea458a246bbe8256ce48aad2806.

  • Document appraisal and national European sources remain open.
  • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

Showing 2 of 2 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. EMA EU/3/16/1689 — include: EMA orphan feed identifies teriparatide; designation status: Positive. Orphan designation is not marketing authorization.
  2. EMA EU/3/20/2350 — exclude: Different analogue, conjugate or glucagon-like peptide; the name match does not identify the unmodified catalog molecule.

ClinicalTrials.gov search

ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.

214 retrieved · 0 included · 0 excluded · 214 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

"Teriparatide" OR "parathyroid hormone (1-34)" OR "PTH(1-34)" OR "Kauliv" OR "Zandoriah" OR "Terrosa" OR "Movymia" OR "Sondelbay" OR "Forsteo" OR "Livogiva" OR "Teriparatide Sun" OR "Teriparatide Ascend" OR "Teriparatide Cinnagen" OR "Qutavina"

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:27:08.738574+00:00 · HTTP 200 · SHA-256 3978e67beee3417e4f2b4769853ca56abab1d275f4a00975279890fb666dbac5.

  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:27:10.318121+00:00 · HTTP 200 · SHA-256 615d1a7a116bc4dd9a5290532269422d352f62a2253cb07287fc32a62d0ad80a.

  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:27:11.237419+00:00 · HTTP 200 · SHA-256 4821050bf5a235fffb0220a7d512f9d0d53ac8b89d435b73cad5d65e2d80253f.

  • Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
  • Other registries, unregistered studies and additional aliases remain outside this query.

Showing 25 of 214 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. ClinicalTrials.gov NCT03232476 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  2. ClinicalTrials.gov NCT01063504 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  3. ClinicalTrials.gov NCT05993130 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  4. ClinicalTrials.gov NCT04879420 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  5. ClinicalTrials.gov NCT00741182 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  6. ClinicalTrials.gov NCT01896011 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  7. ClinicalTrials.gov NCT01250145 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  8. ClinicalTrials.gov NCT01945788 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  9. ClinicalTrials.gov NCT03623633 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  10. ClinicalTrials.gov NCT06842758 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  11. ClinicalTrials.gov NCT00696644 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  12. ClinicalTrials.gov NCT07028320 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  13. ClinicalTrials.gov NCT00079924 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  14. ClinicalTrials.gov NCT00131469 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  15. ClinicalTrials.gov NCT04241211 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  16. ClinicalTrials.gov NCT02932501 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  17. ClinicalTrials.gov NCT02440581 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  18. ClinicalTrials.gov NCT06061354 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  19. ClinicalTrials.gov NCT02090244 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  20. ClinicalTrials.gov NCT00393380 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  21. ClinicalTrials.gov NCT01801397 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  22. ClinicalTrials.gov NCT01796301 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  23. ClinicalTrials.gov NCT05387070 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  24. ClinicalTrials.gov NCT00347737 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  25. ClinicalTrials.gov NCT06951776 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
Read the full Human Evidence Review

Supervised synthesis

What do selected human studies report about Teriparatide?

Manually reviewed August 19, 2026 · version 1

Browse all Human Evidence Reviews · Open preserved synthesis version 1 →

A bounded review of two randomized fracture trials in postmenopausal women with osteoporosis, including one placebo comparison and one active comparison with risedronate.12

Bottom line from this bounded source set

Both reviewed trials reported fewer new vertebral fractures with teriparatide than with the comparator. The active-comparator trial did not find a statistically significant difference for its nonvertebral fragility-fracture endpoint.12

Reviewed study record

Placebo-controlled fracture trial

Design

A randomized placebo-controlled trial assessed new vertebral and nonvertebral fractures and bone mineral density over a median observation period of 21 months.1

Population

The trial randomized 1,637 postmenopausal women with osteoporosis and prior vertebral fractures.1

Outcomes reported

New vertebral fractures occurred in 14% of the placebo group and 5% and 4% of the two teriparatide groups; nonvertebral fragility fractures occurred in 6% and 3%, respectively.1

Limitations

The population had established postmenopausal osteoporosis with prior vertebral fractures, so the results do not establish effects in people with different baseline risk.1

Reviewed study record

VERO active-comparator fracture trial

Design

A sponsor-funded, double-blind, double-dummy randomized trial compared teriparatide with risedronate over 24 months, with new radiographic vertebral fractures as the primary outcome.2

Population

The trial randomized 1,360 postmenopausal women with severe osteoporosis and qualifying vertebral fractures.2

Outcomes reported

New vertebral fractures were reported in 5.4% of the teriparatide group and 12.0% of the risedronate group. The reported nonvertebral fragility-fracture difference was not statistically significant.2

Limitations

The sponsor-funded results apply to women with severe osteoporosis and existing vertebral-fracture history; the nonvertebral endpoint remained statistically uncertain.2

Reviewed source set

  1. PubMed · 11346808Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis ↗PubMed PMID 11346808 · EFetch XML reviewed 2026-08-19 · payload SHA-256 6e178a71aed55efb345f0b59ad938e7c5c0db5692d911f30c23ae4d66e0627b2
    No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1056/nejm200105103441904. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  2. PubMed · 29129436Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial ↗PubMed PMID 29129436 · EFetch XML reviewed 2026-08-19 · payload SHA-256 36f2e43b6083d116716442ec30a08f20413f3bbae83e308678d58c0ec185b2f1
    No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1016/s0140-6736(17)32137-2. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Teriparatide?

U.S. label record. The cited DailyMed label identifies Teriparatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗

The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.

149Dated records56PubMed records73Trial records20Regulatory records

Evidence present

What records are connected here?

Evidence lanes
3
Source years
24
Drugs@FDA applications
6

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Open the complete timeline →Browse all connected recordsFollow via RSS
Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Teriparatide?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

149Selected dated records
150Connected citations
24Populated source years1999–2026
3/4Record lanes present
Clinical trials73Open matching records →Literature metadata56Open matching records →Regulatory20Open matching records →Safety0No selected dated records

Registered human studies

Trial composition

9 of 73 selected trial records include at least one phase value; 10 of 73 include a status value in the retained structured contract.

601 public history versions connect to 71 of these trial records across 22 submitted years. Open the record-history collection →

1 exact source-declared trial-publication link connects selected NCT and PMID records. Open the exact graph →

PhasesPhase 3 4Phase 4 3Phase 2 2
Status at observationCompleted 9Recruiting 1

A phase value is unavailable here for 64 selected records; this is not counted as “no phase.”

A status value is unavailable here for 63 selected records; this is not counted as a trial status.

PubMed bibliography

Publication composition

29 of 56 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 27Review 9Research Support, Non-U.S. Gov't 6Comparative Study 4Randomized Controlled Trial 3Case Reports 2Letter 2Multicenter Study 2Clinical Trial 1Comment 1English Abstract 1Observational Study 1

Bibliography fields unavailable here for 27 selected records; the records remain visible as metadata observations.

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
6
FDA Federal Register documents
6
DailyMed SPL versions
8
Canonical profile
Published
Profile structured data
Published
Linked dated records
149

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts

Exact identifier graph

1 trial-publication link for Teriparatide

Open the full graph →

These links come only from structured NCT and PMID identifiers declared by PubMed or ClinicalTrials.gov. They do not summarize the publications or establish findings.

Research hub

Explore the Teriparatide evidence record

Open all 149 records →
149Dated records
3Evidence types
149Cited public sources
24Source years

Change ledger

Recently changed for Teriparatide

Open all 150 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT02025179

PeptideScanner retained ClinicalTrials.gov record NCT02025179 at 2026-07-30T19:13:03.751Z. Its registry update date was 2023-05-10, and PeptideScanner's reviewed identity mapping was teriparatide.

PeptideScanner change date
September 9, 2026
Cited source date
May 10, 2023
Evidence lane
Clinical trials
Open the cited record →
Cited source
Record added

ClinicalTrials.gov record NCT04750460

PeptideScanner retained ClinicalTrials.gov record NCT04750460 at 2026-07-30T19:32:59.860Z. Its registry update date was 2022-11-10, and PeptideScanner's reviewed identity mapping was teriparatide.

PeptideScanner change date
September 9, 2026
Cited source date
November 10, 2022
Evidence lane
Clinical trials
Open the cited record →
Cited source
Record added

Early callus formation in human hip fracture treated with internal fixation and teriparatide.

PubMed lists PMID 18843769 in The Journal of rheumatology as Case Reports, Letter, with publication-date metadata of 2008-10 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
September 9, 2026
Cited source date
November 21, 2013
Evidence lane
Literature metadata
Open the cited record →
Cited source

Official-source collections

Source records for Teriparatide

Open the full research atlas →
PubMed56

29 with attributed title, venue, publication-date, and type metadata.

Journal Article (27)Review (9)Research Support, Non-U.S. Gov't (6)
  1. Transient teriparatide for postoperative hypocalcaemia with hungry bone features.European journal of endocrinology · 2026 08 13
  2. Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: Research Summary.JAMA · 2026 07 14
  3. Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial.JAMA · 2026 Jul 14
Explore all selected literature →
ClinicalTrials.gov73

601 public history versions across these dated registry records; status labels apply only to each cited observation.

Recruiting history (301)Completed history (123)Active Not Recruiting history (116)
Current at observation (11)Completed at observation (62)
Osteoporosis (4)Osteoporosis, Postmenopausal (3)Postmenopausal Osteoporosis (2)Phase 3 (4)Phase 4 (3)Completed (9)Recruiting (1)
teriparatide · Drug (5)Teriparatide · Drug (5)
  1. NCT06164795Registry update July 22, 2026 · current at observation
  2. NCT01293292Registry update May 19, 2026 · completed at observation
  3. NCT03770338Registry update May 14, 2026 · current at observation
Explore all selected trial records →Explore all public record history →
Drugs@FDA6

Original-submission application metadata connected by exact reviewed active-ingredient names.

  1. ANDA213641Full FDA chronology · original submission status AP 2025-12-12
  2. NDA218771Full FDA chronology · original submission status AP 2024-06-04
  3. ANDA208569Full FDA chronology · original submission status AP 2023-11-16
  4. ANDA211097Full FDA chronology · original submission status AP 2023-11-16
  5. NDA211939Full FDA chronology · original submission status AP 2019-10-04
Explore all selected FDA applications →Explore 38 dated submissions and 57 documents for Teriparatide →
DailyMed SPL history8

Version metadata and exact historical ZIP receipts for the reviewed label family, without reproducing or interpreting label text.

  1. SPL version 9Published 2026-06-30 · ZIP SHA-256 3d44d13e5c26…
  2. SPL version 8Published 2025-07-16 · ZIP SHA-256 8cf27ba70e1f…
  3. SPL version 7Published 2025-05-12 · ZIP SHA-256 83b0e180261f…
  4. SPL version 6Published 2024-12-30 · ZIP SHA-256 d333cbb54ff5…
  5. SPL version 5Published 2024-07-04 · ZIP SHA-256 da12c35fbadc…
Explore all DailyMed label versions →

Counts and links describe PeptideScanner’s selected records. They are not rankings and do not establish research quality, safety, effectiveness, or medical relevance.

Evidence types

Coverage by source year

Selected records span September 22, 1999 to August 13, 2026.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Leuprolide21 shared source years215 dated records · 4 evidence typesOctreotide21 shared source years160 dated records · 4 evidence typesExenatide19 shared source years119 dated records · 3 evidence typesGlucagon17 shared source years308 dated records · 4 evidence types

These dates come from selected source records and PubMed metadata. They are not a complete or continuous timeline of research, safety, approval, or effectiveness.

Evidence summary

What the cited records say

The cited DailyMed label identifies Teriparatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗

This is a source summary, not a medical recommendation. Status may differ by jurisdiction and product.

Cited context

Related records

Organizations named in cited records

  • U.S. National Library of Medicine↗

Dated source history

Updates connected to this profile

Open the full cross-source timeline →

  1. Literature metadata

    Letter to the Editor: "Comparison of Teriparatide and Denosumab in Patients Switching from Long-Term Bisphosphonate Use".↗

    PubMed lists PMID 31408164 in The Journal of clinical endocrinology and metabolism as Comment, Letter, with publication-date metadata of 2019-12-01 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Targeted drug repurposing in medication-related osteonecrosis of the jaw: a review of teriparatide and pentoxifylline/α-tocopherol protocols.↗

    PubMed lists PMID 41852535 in Frontiers in medicine as Journal Article, Review, with publication-date metadata of 2026-03-03 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Teriparatide in Two Patients With Mucopolysaccharidosis Type IVB.↗

    PubMed lists PMID 41987916 in JIMD reports as Journal Article, with publication-date metadata of 2026-04-13 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Comparing Teriparatide and Bisphosphonates for Postmenopausal Osteoporosis: A Systematic Review and Meta-Analysis of RCTs.↗

    PubMed lists PMID 42022682 in Health science reports as Journal Article, Review, with publication-date metadata of 2026-03-13 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Acute use of teriparatide and palopegteriparatide in the management of hungry bone syndrome following parathyroidectomy.↗

    PubMed lists PMID 42058698 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2026-04-28 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    A Comparison Between Bisphosphonates and Teriparatide in the Treatment of Postmenopausal Osteoporosis: A Systematic Review.↗

    PubMed lists PMID 42083710 in Cureus as Journal Article, Review, with publication-date metadata of 2026-04-03 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    Transient teriparatide for postoperative hypocalcaemia with hungry bone features.↗

    PubMed lists PMID 42592840 in European journal of endocrinology as Journal Article, with publication-date metadata of 2026-08-13 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    PubMed record PMID 42568899↗

    PeptideScanner retained PubMed bibliographic metadata for PMID 42568899 at 2026-08-10T10:49:13.608Z. PubMed recorded a metadata revision date of 2026-08-08 and an Entrez history date of 2026-08-08. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.↗

  9. Literature metadata

    PubMed record PMID 42570209↗

    PeptideScanner retained PubMed bibliographic metadata for PMID 42570209 at 2026-08-10T10:49:13.625Z. PubMed recorded a metadata revision date of 2026-08-08 and an Entrez history date of 2026-08-08. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.↗

  10. Literature metadata

    PubMed record PMID 42501079↗

    PeptideScanner retained PubMed bibliographic metadata for PMID 42501079 at 2026-08-10T10:49:10.788Z. PubMed recorded a metadata revision date of 2026-08-07 and an Entrez history date of 2026-07-25. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.↗

  11. Literature metadata

    PubMed record PMID 41904726↗

    PeptideScanner retained PubMed bibliographic metadata for PMID 41904726 at 2026-08-10T10:49:08.825Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-03-29. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.↗

  12. Literature metadata

    PubMed record PMID 41949681↗

    PeptideScanner retained PubMed bibliographic metadata for PMID 41949681 at 2026-08-10T10:49:08.835Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-04-08. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.↗

Public beta · Selective source coverageNot medical advice · No dosing or purchasing guidance